Genetics or environment in drug transport: The case of organic anion transporting polypeptides and adverse drug reactions

John D. Clarke, Nathan J Cherrington

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drugdrug interactions and the physiological context of liver diseases. Liver diseases such as non-alcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. Areas covered: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. Expert opinion: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.

Original languageEnglish (US)
Pages (from-to)349-360
Number of pages12
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume8
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Anions
Peptides
Pharmaceutical Preparations
Liver
Liver Diseases
Polymorphism
Single Nucleotide Polymorphism
Protein Isoforms
Nucleotides
Genetics
Pharmacokinetics
Cholestasis
Expert Testimony
Substrate Specificity
Epigenomics
Hepatocellular Carcinoma
Pharmacology

Keywords

  • Adverse drug reaction
  • Drug metabolism
  • Non-alcoholic fatty liver disease
  • Organic anion transport polypeptide
  • Pharmacogenetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{27edc367cefa4f72b008cdfdef296fc2,
title = "Genetics or environment in drug transport: The case of organic anion transporting polypeptides and adverse drug reactions",
abstract = "Introduction: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drugdrug interactions and the physiological context of liver diseases. Liver diseases such as non-alcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. Areas covered: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. Expert opinion: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.",
keywords = "Adverse drug reaction, Drug metabolism, Non-alcoholic fatty liver disease, Organic anion transport polypeptide, Pharmacogenetics",
author = "Clarke, {John D.} and Cherrington, {Nathan J}",
year = "2012",
month = "3",
doi = "10.1517/17425255.2012.656087",
language = "English (US)",
volume = "8",
pages = "349--360",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Genetics or environment in drug transport

T2 - The case of organic anion transporting polypeptides and adverse drug reactions

AU - Clarke, John D.

AU - Cherrington, Nathan J

PY - 2012/3

Y1 - 2012/3

N2 - Introduction: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drugdrug interactions and the physiological context of liver diseases. Liver diseases such as non-alcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. Areas covered: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. Expert opinion: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.

AB - Introduction: Organic anion transporting polypeptide (OATP) uptake transporters are important for the disposition of many drugs and perturbed OATP activity can contribute to adverse drug reactions (ADRs). It is well documented that both genetic and environmental factors can alter OATP expression and activity. Genetic factors include single nucleotide polymorphisms (SNPs) that change OATP activity and epigenetic regulation that modify OATP expression levels. SNPs in OATPs contribute to ADRs. Environmental factors include the pharmacological context of drugdrug interactions and the physiological context of liver diseases. Liver diseases such as non-alcoholic fatty liver disease, cholestasis and hepatocellular carcinoma change the expression of multiple OATP isoforms. The role of liver diseases in the occurrence of ADRs is unknown. Areas covered: This article covers the roles OATPs play in ADRs when considered in the context of genetic or environmental factors. The reader will gain a greater appreciation for the current evidence regarding the salience and importance of each factor in OATP-mediated ADRs. Expert opinion: A SNP in a single OATP transporter can cause changes in drug pharmacokinetics and contribute to ADRs but, because of overlap in substrate specificities, there is potential for compensatory transport by other OATP isoforms. By contrast, the expression of multiple OATP isoforms is decreased in liver diseases, reducing compensatory transport and thereby increasing the probability of ADRs. To date, most research has focused on the genetic factors in OATP-mediated ADRs while the impact of environmental factors has largely been ignored.

KW - Adverse drug reaction

KW - Drug metabolism

KW - Non-alcoholic fatty liver disease

KW - Organic anion transport polypeptide

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84857349066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857349066&partnerID=8YFLogxK

U2 - 10.1517/17425255.2012.656087

DO - 10.1517/17425255.2012.656087

M3 - Article

C2 - 22280100

AN - SCOPUS:84857349066

VL - 8

SP - 349

EP - 360

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 3

ER -